Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Significant Increase in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 289,475 shares, an increase of 27.2% from the February 26th total of 227,623 shares. Approximately 1.8% of the company’s shares are sold short. Based on an average daily trading volume, of 256,750 shares, the days-to-cover ratio is currently 1.1 days.

Institutional Trading of Allarity Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC purchased a new stake in shares of Allarity Therapeutics during the second quarter valued at $27,000. XTX Topco Ltd purchased a new position in Allarity Therapeutics in the 4th quarter worth about $36,000. Geode Capital Management LLC increased its stake in Allarity Therapeutics by 49.3% in the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after buying an additional 16,729 shares during the period. Citadel Advisors LLC bought a new stake in Allarity Therapeutics during the 3rd quarter valued at about $149,000. Finally, Capital Advisors Inc. OK bought a new stake in Allarity Therapeutics during the 4th quarter valued at about $108,000. 11.53% of the stock is currently owned by institutional investors.

Allarity Therapeutics Stock Performance

ALLR opened at $1.09 on Wednesday. The stock’s 50 day moving average price is $1.05 and its 200-day moving average price is $1.21. Allarity Therapeutics has a one year low of $0.61 and a one year high of $2.35. The stock has a market cap of $17.53 million, a price-to-earnings ratio of -1.36 and a beta of 0.20.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. The business had revenue of $0.32 million for the quarter. As a group, analysts predict that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ALLR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. Ascendiant Capital Markets raised their target price on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $9.50.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical?stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small?molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid?stage clinical trials.